ID: h-41b54533e6
Hypothesis
A lower-dose 50-100 mg/day glial anti-inflammatory effect may occur, but is unlikely by itself to establish disease modification
Trazodone may have a secondary low-dose mechanism through astrocyte and microglial inflammatory modulation, potentially shifting GFAP, IL-6, YKL-40, or kynurenine-pathway markers.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 7 support✗ 3 oppose
🧪 Overview
Trazodone may have a secondary low-dose mechanism through astrocyte and microglial inflammatory modulation, potentially shifting GFAP, IL-6, YKL-40, or kynurenine-pathway markers. This is the weakest surviving biological mechanism worth embedding in a trial as a secondary pharmacodynamic package, not as a lead disease-modifying hypothesis.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["AIF1 / IBA1<br/>Allograft Inflammatory Factor 1"]
B["Microglial Activation Marker<br/>Divalent Calcium Binding"]
C["F-actin Crosslinking<br/>Membrane Ruffling and Phagocytosis"]
D["Pro-inflammatory Signaling<br/>NLRP3 and NF-kB Upregulation"]
E["Synaptic Pruning Enhancement<br/>C1q and C3 Deposition"]
F["Cytokine Release<br/>IL-1beta and TNF-alpha Secretion"]
G["AIF1 Upregulation<br/>Chronic Neuroinflammation Marker"]
A --> B
B --> C
C --> D
D --> E
D --> F
G -.->|"reflects"| D
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style D fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a⚖️ Evidence
⚖️ Evidence Matrix7 supports3 contradicts
Supports
Trazodone protected neuronal-like cells from inflammatory injury via NF-kB, p38, and JNK pathway modulation.
Supports
Human microglial experiments reported reduced IL-6, TGF-beta, IBA1, and quinolinic acid release after trazodone exposure.
Supports
Hepatic encephalopathy induces anxiety and depression-like behaviors, cytokine dysfunction, BDNF down-regulation and neuropathological changes in mice.
Supports
Narirutin reduces microglia-mediated neuroinflammation by inhibiting the JAK2/STAT3 pathway in MPP(+)/MPTP-induced Parkinson's disease models.
Supports
[Tetrahydropalmatine acts on α7nAChR to regulate inflammation and polarization of BV2 microglia].
Supports
Zunyimycin C enhances immunity and improves cognitive impairment and its mechanism.
Supports
Development of New IL-1R Antagonists with Improved Anti-inflammatory Efficacy.
Contradicts
Most support comes from in vitro or cell-based systems far removed from dementia brain pharmacology.
Contradicts
Inflammatory biomarker shifts do not necessarily imply slower neurodegeneration in dementia.
Contradicts
No human dementia study has shown that low-dose trazodone changes inflammatory markers in parallel with clinical or structural benefit.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — IL6;
No curated PDB or AlphaFold mapping for IL6; yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for IL6; TGFB1; AIF1; MAPK14; MAPK8; NFKB1 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for IL6; TGFB1; AIF1; MAPK14; MAPK8; NFKB1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0178
Events (7d)
1
Price History
▲1.4%💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF early Alzheimer's disease patients (n≥40/arm) receive trazodone 50-100 mg/day versus placebo for 12 weeks, THEN CSF GFAP concentrations will decrease by ≥15% from baseline in the active treatment g | CSF GFAP will decrease by ≥15% from baseline in the trazodone arm compared to placebo, reflecting reduced astrocyte reactivity. | — no observation — | pending | 0.48 |
| IF early Alzheimer's disease or MCI patients (n≥60/arm) are randomized to receive trazodone 50-100 mg/day versus placebo for 12 weeks, THEN serum IL-6 levels will decrease by ≥20% from baseline in the | Serum IL-6 will show a statistically significant reduction (p<0.05) with ≥20% decrease from baseline after 12 weeks of low-dose trazodone. | — no observation — | pending | 0.55 |
🔮 Falsifiable Predictions (2)
pendingconf 55%
IF early Alzheimer's disease or MCI patients (n≥60/arm) are randomized to receive trazodone 50-100 mg/day versus placebo for 12 weeks, THEN serum IL-6 levels will decrease by ≥20% from baseline in the treatment arm.
Predicted outcome: Serum IL-6 will show a statistically significant reduction (p<0.05) with ≥20% decrease from baseline after 12 weeks of low-dose trazodone.
Falsification: Serum IL-6 fails to decrease by ≥20% from baseline, OR shows no significant difference from placebo (p≥0.05), OR increases above baseline in the trazodone arm.
pendingconf 48%
IF early Alzheimer's disease patients (n≥40/arm) receive trazodone 50-100 mg/day versus placebo for 12 weeks, THEN CSF GFAP concentrations will decrease by ≥15% from baseline in the active treatment group.
Predicted outcome: CSF GFAP will decrease by ≥15% from baseline in the trazodone arm compared to placebo, reflecting reduced astrocyte reactivity.
Falsification: CSF GFAP fails to show ≥15% reduction from baseline in the trazodone arm, OR shows no significant difference from placebo (p≥0.05), indicating no meaningful glial anti-inflammatory effect at this dose
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.